TG Therapeutics Inc. (NASDAQ: TGTX) announced positive results from a phase 1 study of subcutaneous BRIUMVI in patients with myasthenia ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE